Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2022 • ACR Convergence 2025
Clinical Predictors of Macrophage Activation Syndrome and Treatment Outcomes in Adult-Onset Still’s Disease: A 24-Year Single-Center Experience
Oguzhan Omer Kizilkaya¹, Beste Acar¹, Berkay Aktas¹, Ozgur Can Kilinc¹ and serdal Ugurlu², ¹Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare autoinflammatory disorder with heterogeneous manifestations. Its most severe complication, macrophage activation syndrome (MAS), occurs in up to…
Abstract Number: 1448 • ACR Convergence 2025
Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
Laure Gossec¹, Pascal Claudepierre², Arnaud Constantin³, Denis Jullien⁴, Samira Chaalal⁵, Julie Baraut⁵, Laure Cipiere⁵, Laurène Gautier⁶, Pierre Lemire⁷ and Thierry Passeron⁸, ¹Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ²Department of Rheumatology, CHU Henri Mondor, AP-HP, Créteil, France, Creteil, France, ³Department of Rheumatology, Toulouse University Hospital, Toulouse University and INSERM U¹²⁹¹, France, Toulouse, France, ⁴Hospices Civils de Lyon, Hôpital E. Herriot Department of Dermatologie, Lyon F-⁶⁹⁰⁰³ ; CIRI, Centre International de Recherche en Infectiologie, Team EIA : Epidermal immunity & Allergy, INSERM, U¹¹¹¹; Univ Lyon; Université de Lyon ¹; Ecole Normale Supérieure de Lyon; CNRS, UMR ⁵³⁰⁸, Lyon, France., Lyon, France, ⁵Johnson & Johnson, Issy les moulineaux, France, ⁶Johnson & Johson, Issy les Moulineaux, France, ⁷IQVIA, Real World Solutions, Paris, France, Paris, France, ⁸Johnson & Johnson, Nice, France
Background/Purpose: Psoriatic disease, including psoriasis (Pso) and psoriatic arthritis (PsA), seems to affect male and female patients differently in clinical presentation, disease progression and advanced…
Abstract Number: 1178 • ACR Convergence 2025
An International modified Delphi Study on the evolving role of Janus kinase inhibitors (JAKi) in rheumatic and musculoskeletal diseases (RMDs)
Anna Barkaway¹, Philip J. Mease², Zoe Rutter-Locher³, Robert Moots⁴, Mwidimi Ndosi⁵ and Michael McLean⁶, ¹Pfizer UK, Tadworth, United Kingdom, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Guys and St Thomas NHS trust, London, United Kingdom, ⁴Liverpool University Hospitals, Liverpool, United Kingdom, ⁵University of the West of England, Bristol, Filton, United Kingdom, ⁶Pfizer, Glasgow, United Kingdom
Background/Purpose: The development of advanced therapies such as JAK inhibitors (JAKi) has expanded treatment options available for patients with rheumatic and musculoskeletal diseases (RMDs). Case…
Abstract Number: 0589 • ACR Convergence 2025
Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials
Sofia Ramiro¹, Anna Molto², Elena Nikiphorou³, Marcelo Pinheiro⁴, Jamie Urbanik⁵, Tianming Gao⁶, Shirley Chen⁷, Jayne Stigler⁸, Jessica A. Walsh⁹ and Lihi Eder¹⁰, ¹Leiden University Medical Center, Bunde, Netherlands, ²Assistance Publique Hôpitauxde Paris, Paris, France, ³King's College London, London, United Kingdom, ⁴UNIFESP/ EPM, São Paulo, São Paulo, Brazil, ⁵AbbVie, Grayslake, IL, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Somerset, NJ, ⁸AbbVie, Round Lake, IL, ⁹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ¹⁰University of Toronto, Toronto, ON, Canada
Background/Purpose: Evidence suggests that the treatment effectiveness of TNFis and IL-17is is higher in male (M) vs female (F) patients (pts) with axSpA.1,2 Data comparing…
Abstract Number: 0505 • ACR Convergence 2025
Use of Upadacitinib in Real-World Clinical Practice: Patient Characteristics and Glucocorticoid-Sparing Effect
Virginia Ruiz-Esquide¹, Lourdes Mateo², Carolina Pérez García³, Hye Sang-Park⁴, Susana Holgado⁵, María Aparicio⁶, Beatriz Frade⁷, Juan Camilo Sarmiento-Monroy⁸, Annika Nack⁹, Felipe Julio Ramirez Garcia¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí¹, ¹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ²Hospital Trías i Pujol, Barcelona, Catalonia, Spain, ³Hospital del Mar, Barcelona, Spain, ⁴Hospital Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain, ⁶Hospital Germans Trías i Pujol, Badalona, Catalonia, Spain, ⁷Hospotal Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Hospital Germans Trias i Pujol, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: While clinical trials have demonstrated the efficacy of upadacitinib (UPA), real-world data are essential to understand patient characteristics and assess its effectiveness in routine…
Abstract Number: 0444 • ACR Convergence 2025
Low Disease Activity: Good Enough?
Emily Thoman¹, Sebastiano Porcu¹ and Martin Bergman², ¹Lankenau Medical Center, Wynnewood, PA, ²Drexel University College of Medicine, Philadelphia
Background/Purpose: Treat-to-target is the guiding principle and therapeutic strategy for rheumatoid arthritis (RA) treatment. Escalation of treatment is based on the regular assessment of disease…
Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Francesco Fulvio Bizzarri¹, Luis Alberto Menchén Viso², Esther Chamorro De Vega³, Ofelia Baniandrés Rodríguez⁴ and Juan Carlos Nieto², ¹Hospital Universitario Clinico San Cecilio, Granada, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…
Abstract Number: 1985 • ACR Convergence 2025
Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Rachel Galvao, Anokhi Saklecha, Julia Stevenson, Ritche Hao, Eugenia Chock and Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Teratogenic medications are commonly prescribed to women of reproductive age who have rheumatic conditions. Counseling on teratogenicity and contraception is critical to reducing patients’…
Abstract Number: 1442 • ACR Convergence 2025
Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Ayumu Sugiura³, Jay Tang¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³, Paresh Thakker¹ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: As a chronic inflammatory disease, PsA is marked by cartilage and bone turnover and articular inflammation. Accordingly, elevated levels of inflammation and bone metabolism…
Abstract Number: 1155 • ACR Convergence 2025
Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
Nada Elbuluk¹, Melinda J. Gooderham², Jessamyn Blau³, Wenwen Zhang³, Ejim Mark³, Warren Winkelman³ and Mark Lebwohl⁴, ¹Department of Dermatology, USC Keck School of Medicine, Los Angeles, CA, ²SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ³Takeda Development Center Americas, Inc., Cambridge, MA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Zasocitinib (TAK-279) is an investigational, highly selective and potent, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor. In a phase 2b trial of moderate-to-severe plaque…
Abstract Number: 0588 • ACR Convergence 2025
The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
Casper Webers¹, AUGUSTA ORTOLAN², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: In axial spondyloarthritis (axSpA), peripheral musculoskeletal manifestations (peripheral arthritis, enthesitis, dactylitis) are common and contribute to the burden of disease. Our objective was to…
Abstract Number: 0502 • ACR Convergence 2025
Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study
Satani Sharkas¹, Saeed Abughazaleh² and Dariush Jahandideh³, ¹Boston Medical Center - Brighton, Brighton, MA, ²Boston Medical Center - Brighton, Brighton, ³Boston Medical Center - Brighton, Boston
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are approved treatments for rheumatoid arthritis (RA). However, comparative safety data on cardiovascular outcomes and all-cause mortality…
Abstract Number: 0400 • ACR Convergence 2025
Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Daniel Horton¹, Charu Verma², Sanika Rege², Alicia Iizuka², Matthew Iozzio³, Dawn Koffman³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard², Lauren Parlett⁶, Carlos Rose⁷ and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, ⁴Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ⁵New Jersey Medical School, Newark, NJ, ⁶Carelon Research, Inc, Wilmington, DE, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, New Brunswick
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatic disease, has been tied to microbiome disruption (dysbiosis). Dysbiosis in adults with arthritis affects response…
Abstract Number: L09 • ACR Convergence 2024
Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine Brunner¹, Caifeng Li², Kogie Chinniah³, Yosef Uziel⁴, Olga Synoverska⁵, Sujata Sawhney⁶, Inmaculada Calvo Penades⁷, Ingrid Clara Louw⁸, Meiping Lu⁹, Pooja Nikunj Patel¹⁰, Pamela F. Weiss¹¹, Cheng Chang¹², Ivana Vranic¹³, Shixue Liu¹⁴, Annette Diehl¹⁵, Jose L. Rivas¹⁶, Carol A. Connell¹⁷, Gary G. Koch¹⁸, Alberto Martini¹⁹, Daniel J. Lovell¹, Nicolino Ruperto²⁰ and the PRINTO and PRCSG investigators, ¹Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, ²Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, ³Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, ⁴Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, ⁵Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, ⁶Sir Ganga Ram Hospital, New Delhi, India, ⁷Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁸Panorama Medical Centre, Cape Town, South Africa, ⁹Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ¹⁰Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³Pfizer Ltd, Tadworth, United Kingdom, ¹⁴Pfizer Inc, Shanghai, China, ¹⁵Pfizer Inc, Collegeville, PA, ¹⁶Pfizer SLU, Madrid, Spain, ¹⁷Pfizer Inc, Groton, CT, ¹⁸University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹University of Genoa, Genoa, Italy, ²⁰Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy
Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Fizza Zulfiqar¹, Morgan Steele², Sharanya Shre Ezhilarasan Santhi³, Bryanna Singh², Jaisal Brar³, Sumit Raut³, Prami Nakarmi³, Samhitha Bitla Reddy³, Ojo Ayomide³, Bashar Roumia³, Fariha Tareen³, Nathan Crook³, Vanessa Drust³, Ahmed Fawzy Mohamed³, Asad Mohammad Jani³, Jennifer Orejuela³, Siena Captain³, Nikhil Vojalla³, Muhammad Bilal⁴, Rida Fatima⁴, Sanjana Kesireddy³, Paige Misner³, Rishab Prabhu³, Camelia Arsene³, Jawad Bilal⁵ and Jacky Duong³, ¹Trinity Health Oakland/Wayne State University, Pontiac, MI, ²Trinity Health Oakland, Pontiac, MI, ³Trinity Health Oakland, Pontiac, ⁴Bassett Medical Center, Cooperstown, NY, ⁵Southeast Tucson, Clinician Rheumatologist, Tuscon
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…

« Previous Page
1
…
6
7
8
9
10
…
48
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].